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Background
The efficacy and safety of high dose IL-2 therapy in
patients with brain metastases due to renal cell carci-
noma is not well characterized.
Methods
Data were prospectively collected in a registry of 371
patients with RCC receiving high-dose IL-2, including
18 patients with a history of brain metastases who had
undergone treatment for the brain metastases with
radiation therapy or surgery. The median interval
between the diagnosis of brain metastases and the start
of IL-2 therapy was 7.0 months (range 1-116 months).
Median overall survival in patients with brain metastases
was 15.3 (95% CI 8.0 to not evaluable) months, as com-
pared to 48.0 (95% CI 39.2 to 61.5) months in RCC
patients without any history of brain metastases.
Results
The response to IL-2 in the extra-cranial disease was
assessed. In patients with brain metastases, 0/18 (0%)
had a complete response, 1/18 (5.6%) had a partial
response, and 4/18 (22.2%) had stable disease, whereas
in patients without brain metastases, 15/353 (4.5%)
achieved a complete response, 45/353 (13.4%) achieved
a partial response, and 117/353 (34.8%) had stable dis-
ease. During the first course of IL-2, neurologic adverse
events were reported in 6 subjects (2 events of confu-
sion, 2 events of mental fatigue, 1 event of rigors, and 1
event of anxiety), but no seizures or intracranial hemor-
rhages were reported.
Conclusions
While the efficacy of IL-2 in this population is limited,
the neurologic adverse event rate is acceptably low; in
carefully selected patients with brain metastases, IL-2
may be considered as a therapeutic option but response
rates may be lower than in patients without CNS disease
based on this limited cohort analysis.
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